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András Dinnyés1,3,4* and Kata Filkor1,3,4
1 BioTalentum Ltd, Gödöllő, Hungary, 2 Department of Physiology and Animal Health, Institute of Physiology and Animal
Health, Hungarian University of Agriculture and Life Sciences, Gödöllő, Hungary, 3 Department of Cell Biology and Molecular
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In December 2019, a new viral disease emerged and quickly spread all around the world.
In March 2020, the COVID-19 outbreak was classified as a global pandemic and by June
2021, the number of infected people grew to over 170 million. Along with the patients’
mild-to-severe respiratory symptoms, reports on probable central nervous system (CNS)
effects appeared shortly, raising concerns about the possible long-term detrimental
effects on human cognition. It remains unresolved whether the neurological symptoms
are caused directly by the SARS-CoV-2 infiltration in the brain, indirectly by secondary
immune effects of a cytokine storm and antibody overproduction, or as a consequence of
systemic hypoxia-mediated microglia activation. In severe COVID-19 cases with impaired
lung capacity, hypoxia is an anticipated subsidiary event that can cause progressive and
irreversible damage to neurons. To resolve this problem, intensive research is currently
ongoing, which seeks to evaluate the SARS-CoV-2 virus’ neuroinvasive potential and the
examination of the antibody and autoantibody generation upon infection, as well as the
effects of prolonged systemic hypoxia on the CNS. In this review, we summarize the
current research on the possible interplay of the SARS-CoV-2 effects on the lung,
especially on alveolar macrophages and direct and indirect effects on the brain, with
special emphasis on microglia, as a possible culprit of neurological manifestation during
COVID-19.
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Over the last twenty years, there have been two major new human Coronavirus outbreaks, namely
the SARS-CoV in 2002 in China and the MERS-CoV in 2012 in Saudi Arabia (1, 2). The third novel
Coronavirus outbreak occurred at the end of 2019 caused by SARS-CoV-2 in Wuhan, China (3, 4).
Based on their serological properties, members of the Coronaviridae genus can be grouped into
a, b, g and d coronaviruses. The most pathogenic, pandemic-related human coronaviruses belong to
the b group (5). Coronaviruses have a long, positive-sense, single-stranded RNA genome of 26 to 32org August 2021 | Volume 12 | Article 7300881
Francistiová et al. Microglia in COVID-19kilobases in size. The genome of SARS-CoV-2 contains 14 open
reading frames that encode 27 proteins. At the 5’ region, 15 non-
structural proteins required for viral replication are encoded.
Open reading frames at the 3’ region encode those structural
proteins - namely spike (S), nucleocapsid (N), an envelope
protein (E) and membrane protein (M) - that are required for
infection and induce host immune response (6, 7). In a genome
comparison between SARS-CoV and SARS-CoV-2, it was found
that 79% of both were identical, and the structural organization
of their genomes was the same. In contrast to SARS-CoV, SARS-
CoV-2 and MERS displayed less similarity, as only 50% of their
genome was identical (8).
Although SARS-CoV, MERS-CoV, and SARS-CoV-2 have
strong structural similarities and mainly cause lower respiratory
tract infections and shortness of breath, these viruses have some
unique features. A comparison of these three human pathogenic
coronaviruses is listed in Table 1.
The mildly pathogenic a Coronaviruses cause upper
respiratory tract infections, while the highly pathogenic b
Coronaviruses, including SARS-CoV, MERS-CoV, and SARS-
CoV-2 cause serious lower respiratory tract symptoms (i.e.,
pneumonia), resulting in patients requiring respiratory support
(16). Hence SARS-CoV-2 patients have a high risk of
experiencing severe systemic hypoxia. Along with these,
neurological symptoms may also develop, and the
neuroinvasive tendencies of coronaviruses have been
documented for almost all of the bCoVs, including SARS-CoV,
MERS‐CoV (17), HCoV‐229E (18), HCoV‐OC43 (19) and the
mouse hepatitis virus (20). SARS-CoV-2 also holds the potential
for invading the nervous system. From the documented
neurological symptoms, the mildest ones are anosmia and
ageusia (sudden loss of smell taste) (21), but otolaryngeal
symptoms, i.e., tinnitus, vertigo combined with a loss of
hearing may appear (22). In severe cases, headache, seizures,
delirium and even coma can develop (23). The presence of SARS-Frontiers in Immunology | www.frontiersin.org 2CoV-2 was confirmed in cerebrospinal fluid (CSF) taken from an
encephalitis patient by next-generation sequencing (24) and by
qRT-PCR indicating the presence of viral RNA in CSF (25, 26).
In autopsy brain samples, Puelles and colleagues detected viral
particles (27). Since the brain is one of the so-called immune-
privileged sites of the human body, the investigation of anti-
SARS-CoV-2 immunoglobulin G (IgG) production was also in
focus, as the presence of antibodies in the CSF indicates
intrathecal IgG production (28). However, in some cases,
patients with the presence of SARS-CoV-2 IgG had normal
CSF results, like ICP, cell counts, protein and glucose levels
(29). In another, smaller trial, Barreras and her colleagues
detected SARS-CoV-2 IgG in the CSF of patients with
neurological symptoms. However, IgG levels did not correlate
with the time between symptom development to sampling or
disease severity (30).
There are several possible direct and indirect ways SARS-
CoV-2 could interact with the CNS (31). In this review, we will
discuss these possible interactions together with the impact of
SARS-CoV-2 on alveolar macrophages and focus on the
implications of hypoxia and hypoxia-induced factors on
microglial cells (Figure 1).INTERACTIONS OF SARS-CoV-2 WITH
HOST AND IMMUNE CELLS
Binding to ACE2 on the Host Cells
SARS-CoV-2 uses a transmembrane protein angiotensin-
converting enzyme 2 (ACE2), a metallo-peptidase expressed
not only in the respiratory epithelial cells but in almost every
organ of the body. ACE2 is on the membrane of the target cells to
establish infection (14). Based on its structure, the S-protein
belongs to the class I fusion proteins. It is formed by two
subunits, namely S1 on the N-terminal surface mediatesTABLE 1 | Key comparison of geographical location and epidemiology data of SARS-CoV, MERS and SARS-CoV-2 caused infections.
SARS-CoV MERS SARS-CoV-2 Reference
Outbreak November, 2002 April, 2012 December, 2019 (3, 9, 10)
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on the C-terminal, is responsible for the internalization of the
virion in the host cell (32).The binding affinity between the S
protein of SARS-CoV-2 and the ACE2 is nearly ten-fold higher
than in the case of SARS-CoV. Besides the attachment to the host
ACE2 receptor, the priming of S protein by transmembrane
protease serine 2 (TMPRSS2), a host membrane serine protease
on the cell membrane, is also needed to permit the entry of the
SARS-CoV-2 (33). Upon the formation of the bond,
conformation changes take place in the S protein. It is cleaved
by TMPRSS2, thereby allowing the release of the S2 subunit, and
facilitating the entry of viral RNA into the cytoplasm of the host
cell (32). As potential strategies for the treatment of COVID-19,
the pharmacological inhibition of TMPRSS2 or the bond
between human recombinant soluble ACE2 and the receptor-
binding domain of S-protein could significantly reduce infection
by SARS-CoV-2 (34) (Figure 2A).
The ACE2 receptor plays a physiological role in the renin-
angiotensin system, and it indirectly affects the signaling
pathway. ACE2 converts Angiotensin II (Ang II) into
Angiotensin 1-7 [Ang-(1-7)], which binds to the Mas receptor
that has a protective role in the lungs, as well as in other organs.
However, in the case of Ang II binding to its receptor, vascular
permeability can be facilitated by the JAK/STAT signaling
pathway (35). During acute lung injury fibrosis, and when
patients are exposed to the SARS-CoV-2 infection, ACE
inhibitors and Ang II receptor blockers (ARBs) could moderate
the lung injury by shifting the system towards the protective
pathway [ACE2/Ang-(1-7)] (36). ACE inhibitors reduce
hypertension which is common among patients with SARS-
CoV-2. The concerns related to high blood pressure and
COVID-19 are justified here because the co-occurrence of the
two diseases is relatively high and this has been reported in
several studies (37, 38). Furthermore, ACE2 is cleaved by
increased activity of the transmembrane proteinase
(ADAM17), indicated by the activation of the receptor of the
tumor necrosis factor-a (TNF-a). Upon the release of cytokinesFrontiers in Immunology | www.frontiersin.org 3such as IL-6, IL-1b and IFN-g along with TNF-a due to SARS-
CoV-2 infection, inhibition of the expression of ACE2 has been
reported (35), leading to an imbalance in homeostasis and to
inflammation and a cytokine storm (34).
Primary Immune Evasion Strategy
The primary infected organ of SARS-CoV-2 is the lung causing
acute respiratory distress syndrome (ARDS) and respiratory
failure (39). Initially the virus infects the respiratory epithelial
cells, which highly express ACE2 that provides an excellent entry
for the virus (14). After having formed the bond between the S
protein and ACE2 receptor, the virus can evade the immune
system by effectively inhibiting the activation of TNF receptor-
associated factors (TRAF) 3/6, which are key molecules in
activating downstream signaling such as in interferon
regulatory factor (IRF) 3/7 and nuclear factor kappa B
(NF-kB) signaling pathways (14, 40). Deactivation of further
transcription factors and the suppression of early pro-
inflammatory responses through type I interferon (IFN-I)
signaling, the coronavirus can start limiting antiviral response
mechanisms (14, 41). The evasion of IFN-I-mediated innate
immunity is likely orchestrated by the viral protein N which
acts as an antagonist of IFN signaling. In this scenario, novel
coronaviruses can counteract IFN expression by inhibiting the
phosphorylation and nuclear translocation of transcription
factors of the JAK/STAT signaling pathway (14, 39, 42). The
suppressed expression of IFN-I can lead to an insufficient
response of the host cells and inadequate clearance of viral
infections (43). Thus, the activation of early antiviral programs
appears to be prohibited contributing to the evasion of innate
antiviral immunity by the coronavirus (14, 39). Through the
suppressed expression of IFN-I, virions can regulate IFN-I
signaling in infected macrophages, in which an increased level
of pro-inflammatory cytokine expression (especially TNF-a
and IL-6) via the NF-kB cascade is auto-amplified through
positive feedback loops. These can contribute to triggering
hyperinflammation and to developing a cytokine storm (14, 41).FIGURE 1 | An overview of the topics covered in this review. Our review discusses how SARS-CoV-2 interacts with immune cells with a special focus on alveolar
macrophages. Further, we will discuss how viral particles enter the brain and interacts with microglia cells.August 2021 | Volume 12 | Article 730088
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programs and the recruitment of non-infected immune cells
occur. Virus particles released from the infected dead cells are
recognized by endosomal RNA pattern recognition receptors
(PRRs) which leads to the activation of the innate immune
system and its cellular machinery (39, 44). Recent studies
reported that not only the main RNA sensors, including
cytoplasmic retinoic acid-inducible gene I (RIG-I) and
melanoma differentiation-associated gene 5 (MDA5), have a
key role in the detection and identification of coronavirus
derived PAMPs (45, 46), but also pattern recognition toll-like
receptors 3 and 7 (TLR-3 and TLR-7) are activated. TLRs induce
IFN-I response and further increase the expression of IL-1b, IL-6
and TNF-a through MAVS, IRF3 and NF-kB cascades inFrontiers in Immunology | www.frontiersin.org 4immune cells (14, 44, 47). Therefore, the innate immune
system is activated and macrophages are recruited to the lungs
where hyperinflammation is triggered (14, 41) (Figure 3).
Recruitment of Hypoxic Alveolar
Macrophages
A less prevalent route for the immune evasion of SARS-CoV-2 is
the infection of alveolar macrophages. While the “conventional”
way of the entry of viral particles to the host cells is ACE2-
mediated, in some cases, macrophages can be infected, and this
happens via an antibody/Fcg-mediated route. In this situation,
SARS−CoV−2 virions are recognized by cross reactive
neutralizing antibodies against seasonal coronaviruses (48);
and then are taken up by the macrophage cells via Fcg-
receptors in a mechanism termed antibody directed
enhancement (ADE) (49) (Figure 2B). Once taken up via Fcg
receptors, the virus particles inhibit the signaling of IFN-I in
infected macrophages (14), leading to an increased expression of
pro-inflammatory factors (IL-1b, IL-6 and TNF-a), which might
result in hyperinflammation (14, 41). Besides this, the number of
alveolar macrophages present during SARS-CoV-2 infection
correlates well with disease severity (50). In the case of SARS-
CoV, the delayed release of cytokines and chemokines was found
in bronchial epithelial cells and macrophages at the early stage of
infection in vitro cell experiments (51). Breathing difficulties
caused by disrupted respiratory epithelial cells and the reduced
alveolar partial pressure of oxygen (PO2) induce hypoxia, which
causes inflammation and a hypoxic state in alveolar macrophages
(52). The increased pulmonary expression of significant amounts
of pro-inflammatory cytokines, NF-kB and hypoxia-inducible
factor-1 a (HIF-1a) help uninfected, activated macrophages to
invade into the alveoli, which recruit other immune cells such as
CD8+ T effectors, and this produces more clones and causes
tissue damage (50, 52, 53).
Factors in Alveolar Macrophages
During Hypoxia
In hypoxic alveolar macrophages, the expression of neurokinin-1
receptors is upregulated (52), and this hypoxic event induces the
production of multiple factors such as reactive oxygen species
(ROS) enzymes, transcriptional factors, and MAPKs (54). In the
hypoxic state, when the O2 levels are at 10% instead of the
normoxic 21%, the activated alveolar macrophages contribute to
the release of H2O2, leading to the inflammatory response (55).
Likewise, in SARS-CoV-2, when alveolar macrophages are
infected in the early phase of the disease, the secretion of pro-
inflammatory cytokines (IL-1b, IL-6, IL-18 and TNF-a) and
chemokines (CCL2, CCL3, CCL5) contributes to maintaining the
emerged inflammation (14). Additionally, the autophagy of
macrophages and activation via HIF-1a might result from
hypoxia as well (56). HIF-1a, as a major transcription factor
involved in response to reduced cellular oxygen levels, is
significantly increased in the hypoxic state, while under
physiological conditions, the levels of HIF-1a remain low (56).
In response to hypoxia, increased mRNA, and protein levels of
IL-8 and TNF-a have been observed, and these typicalA
B
FIGURE 2 | To infect the host cell, SARS-CoV-2 can exploit different
receptors. In most infected cells, including epithelial and alveolar cells, the
virus binds to ACE2 receptor (A), while during infection of macrophages, Fcg
receptors are utilized in the antibody-directed enhancement mechanism (B).August 2021 | Volume 12 | Article 730088
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especially by microglia in the CNS (56).
Furthermore, the elevated expression of IFN-a/b and IL-6
can be detected (57), and secreted IFN-l can disrupt the lung
epithelial barrier by inhibiting the lung epithelial proliferation
and its repair directly (58). While SARS-CoV-2 infects the
macrophages, a viral cascade limits the antiviral response
mechanisms by suppressing the activation of transcription
factors (such as NF-kB and IRF3/7), thereby limiting the
release of IFN-Is and allowing the secretion of the above-
mentioned pro-inflammatory cytokines (14, 53). The positive
feedback loops of inflammatory cascade by infected cells may
contribute to hyperinflammation and the cytokine stormFrontiers in Immunology | www.frontiersin.org 5syndrome, the latter of which is also a key factor in
extrapulmonary multiple-organ failure (51).
Factors in the Blood Serum and Cells
Infiltrated to the Bronchoalveolar Fluid
In the blood serum, high levels of C-reactive protein (CRP),
ferritin, and D-dimer emerge during the course of COVID-19
infection (59, 60), suggesting an ongoing strong inflammation
with self-perpetuating tendencies (61). Moreover, the increased
serum levels of CCL7, CXCL10, and IL-1RA, and the presence of
CCL2 and CCL7 in the bronchoalveolar fluid were found,
pointing towards the activation of signaling towards
macrophage recruitment. All of these changes might beFIGURE 3 | A brief overview of the SARS-CoV-2 virus’ immune evasion strategies. After infecting the host cell, the internalization of the viral particle, the
transcription of the viral RNA starts with the translation of ORF1a and ORF2b, which generates proteins participating in the further transcription, host
modulation, and immune evasion (1). In the cell, the presence of viral particles or viral RNA is being recognized by pattern recognition receptors such as toll-like
receptors (TLR), retinoic acid-inducible gene I (RIG-1), and melanoma differentiation-associated protein 5 (MDA5) (2). TLRs (TLR 3, 7, and 8) are localized on
endosomes and together with the cytoplasmatic viral sensors RIG-1 and MDA5, which orchestrate the translocation of NF-kB and IRF3 to the nucleus, leading
to the expression of pro-inflammatory cytokines and type 1 and 3 interferons (INF-1/3). While TLRs activate TNF-associated factor 6 (TRAF6), RIG-1 and MDA5
act through mitochondrial antiviral protein (MAVS), to TRAF3/6, to IRF3/7. Viral protein N and M can alter the ubiquitination and degradation of RIG-1 and MDA5
sensors (3), thus restrains the activation of MAVS, TRAF3/6, and prevents IRF-3/7 and NF-kB signaling. N protein can also counteract IFN-1 production by
inhibition of signal transducer and activator of transcription protein 1 and 2 (STAT1/2) phosphorylation and activation for further signaling (4). Additionally, some
of the non-structural proteins (Nsp3, 8 and others - not shown) can also execute immunomodulatory functions, such as contributing to the inhibition of MDA5
(5a), IRF3 (5b), or stabilizing the NF-kB inhibitor IkBa (5c). Viral protein M also participates in immune evasion by blocking TRAF3 and binding to RIG-1, MDA5,
and MAVS and preventing their interaction (6).August 2021 | Volume 12 | Article 730088
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potentially fatal outcome (62). To explain the elevated levels of
these molecules, the high production of IL-6 and the activated
macrophages should be taken into account. IL-6 is a cytokine of
pleiotropic activity, but during viral infections, IL-6 is considered
one of the most important cytokines for its regulation of T-cell
response, prevention of viral-induced apoptosis of lung epithelial
cells, regulation of IgG isotype switching, and other functions
(63, 64). Moreover, an increased IL-6 level in the serum is
associated with a negative prognosis in patients with SARS-
CoV-2 (65). In COVID-19 patients, the gene expression of
subsets of CD4+ and CD8+ T cells were observed in the
bronchoalveolar fluid, and these subsets were activated
differently; moreover, the B cell populations were altered, while
the monocyte infiltration was minimal (53, 60). Furthermore,
IgG levels declined about two months after symptoms of the
early onset of the disease, but the recovered patients maintained
high spike-specific IgG titers (60). The findings show that many
factors and cells can be present in the blood and in the tissue fluid
after a lung infection.
T Cells and Autoantibodies Involvement in
the CNS
A key component of any immune response, including the
response to SARS-CoV-2, is the activation of CD4+ and CD8+
T cells and the subsequent production of neutralizing antibodies
(66). It is very interesting that the profile of anti-SARS-CoV-2
antibodies in the plasma and CSF differs within the same
COVID-19 patient, suggesting a compartmentalized immune
response within the brain (67). Such divergent humoral
response indirectly supports neuroinvasion of SARS-CoV-2
during acute infection. Longitudinal profiling studies of
neutralizing antibodies against SARS-CoV in 2005 revealed
that recovered SARS patients had developed high levels of
neutralizing antibodies, while patients with a shorter illness
duration displayed higher neutralizing antibody activity
compared to patients with a longer illness duration (68, 69).
This suggests that antibody responses do indeed play a role in
determining the disease outcome. Based on the similarities
between SARS-CoV and SARS CoV -2, it is likely that
neutralizing processes against SARS-CoV-2 antibodies also
develop; and this could contribute to the course, duration, and
possible termination of acute infection in the lung and other
organs, including the CNS.
As is well known, the CNS contains CD4+ and CD8+ T cells,
which patrol and protect the borders of CNS, while CD8+ T cells
provide a cytotoxic defense against viral infections in the brain
parenchyma (70–72). Aside from the direct cytotoxic reactions in
the presence of viral particles in the brain, local cytokine and
chemokine milieu is important for T cell generation, retention
and infiltration to the brain. Thus, T cells might contribute to
cytokine production and further exacerbate inflammatory
conditions in the brain by paracrine signaling to microglia
(73). For this reason, it might be worthwhile examining
the T cell involvement during the course of SARS-CoV-2
infection in the brain-resident T cells. During CNS infectionFrontiers in Immunology | www.frontiersin.org 6with neurotropic viruses, T cells infiltration is followed by B cells
infiltration to ensure local secretion of antibodies since a
passage of antibodies from serum into the brain is prevented
by BBB (74).
Recently, several reports emerged describing the presence of
autoantibodies in high proportions of patients with the most
severe cases. These reports show that about 10% of the tested
patients with severe COVID-19 had antibodies against the type I
interferon molecules and other autoantibodies against proteins
of blood vessels, heart, and brain (75, 76). These findings could
explain the delay in the onset of the severe COVID-19
symptoms, how the “long COVID” develops, and why
sometimes lung damage continues to progress long after the
virus is no longer detectable in the body. Intensive research on
this issue is currently ongoing. It could provide clues on the
possibility that some people might be predisposed to producing
autoantibodies and hence potentially be more likely to develop
severe COVID-19 disease.ENTERING THE BRAIN BY SARS-CoV-2
COVID-19 patients may be at a higher risk of infection of the
nervous system, encephalitis and developing cognitive decline
after displaying symptoms such as olfactory and gustatory
dysfunctions, among others (72). Although CNS is not the
primary organ affected by SARS-CoV-2, viruses can directly
invade the CNS and damage nerves and neurons that were
identified as targets of this viral infection (31). SARS-CoV-2
can migrate by retrograde or anterograde neuronal transport
through motor proteins by infecting motor or sensory nerve
endings (31). Moreover, SARS-CoV-2 can gain access to the
brain either through the olfactory tract or via the lung epithelium
(77) (Figure 4). In several COVID−19 cases, neurological
complications were reported, including mild symptoms such as
confusion, fatigue, anxiety, reversal of sleep-wake cycle, and
headaches (78). But also severe neurological syndromes such as
encephalopathies (79) (often with delirium or psychosis),
meningo-encephalitis (25), ischemic stroke (80), acute
necrotizing encephalopathy (81), and Guillain-Barré syndrome
(82). An impressive cohort study by Peterson et al. provides a
comparative analysis of neurological data from patients with
COVID-19-related neurological disorders. Interestingly, many of
the patients had only mild respiratory symptoms, showing that
these complications were not related to the severity of the
respiratory COVID−19, and thus suggesting that the primary
affected organ was the brain. However, none of the patients
tested for the presence of SARS−CoV−2 protein in CSF were
positive (83). Another cohort study focused on neurological
complications of COVID−19 additionally showed that the
primary neurological impairments in younger patients
comprise psychiatric diagnoses with alterations in mental
status and encephalopathy or encephalitis, while in older
patients (>60 years), the leading neurological complications
were of cerebrovascular origin (84). Although extremely
valuable, these studies present data sets collected from a smallAugust 2021 | Volume 12 | Article 730088
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bias towards severe disease. At the same time, they highlight the
importance of future studies of the neurological complications
accompanying COVID-19 and follow-up studies of the affected
patients that will help uncover the long-term effects of the
disease. In this section, we will explore the possibilities of the
SARS−CoV−2 to directly infect the brain, while in the later
sections, we will discuss the indirect, possibly immune-
overactivation-based routes of COVID−19-related CNS damage.
Viral Entry Through the BBB
The CNS, sometimes described as “immune privileged”, is under
normal conditions carefully sheltered against the invasion of
pathogens from the outside environments as well as from the
periphery. At the forefront of the brain’s immune privilege is the
neurovascular unit, which consists of endothelial cells, associated
blood-brain barrier (BBB) tight junctions (TJ), basal lamina,
pericytes, parenchymal cells, astrocytes, neurons, and
interneurons. The neurovascular unit ensures the maintenance
of the BBB, cerebral homeostasis, and the cerebral blood flow
(85). To further ensure protection against unwanted
inflammation, along with the BBB, which separates the brain
parenchyma from the peripheral blood (86), other biological
barriers are present in the brain. The blood-retina barrier (BRB)
guards the interface with retinae (87), and the blood-Frontiers in Immunology | www.frontiersin.org 7cerebrospinal fluid barrier (BCSFB) isolates the brain from
contact with the CSF (88). Despite such sophisticated defense
mechanisms, the invasion of the CNS by pathogens can occur.
The entry of various pathogens, including viruses, into the CNS
can be facilitated via multiple different routes: such as
transcellular (e.g. by receptor-mediated transport of the viral
particle or by pinocytosis uptake without disruption of the
cellular barriers), paracellular (e.g. by disrupting the tight-
junctions of the BBB and increasing the permeability of the
BBB), as intracellular cargo (the “Trojan horse” method when
the viral particle present inside of a cell is allowed to enter the
CNS by circumventing the BBB) (89). Transcellular entry occurs
as a receptor-mediated uptake or pinocytosis, but the cellular
barriers are not disrupted. A potential target of SARS-CoV-2
infection is the endothelium, especially brain microvascular
endothelial cells (BMVECs), which form the BBB, among other
cell types. After crossing the basement membrane of the lung
epithelium, the virus reaches the blood vessel and then the
BMVECs, to be transported via the cellular pathway by
binding to ACE2 receptor or via an intercellular pathway
across the BBB into the brain (90). Potential direct viral
infection can occur by the biding of the SARS-CoV-2 to ACE2
receptor on the surface of BMVECs. Moreover, internalization
can lead to the production of ROS and the increased secretion of
proinflammatory cytokines as well as chemokines (i.e., CXCL10)FIGURE 4 | Schematic overview of the possible interactions of SARS-CoV-2 and CNS. SARS-CoV-2 particles could potentially and negatively influence the CNS by
multiple means. 1. Directly entering the CNS via crossing the BBB. 2. By-passing the BBB by entering via the olfactory nerve. 3. Indirect influence via microglia
activation by cytokines infiltration from the periphery and hypoxia-induced activation.August 2021 | Volume 12 | Article 730088
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that the coronavirus S1 protein might be cleaved from the virus
by the host cell’s proteases and subsequently be available as a
single infectious unit for crossing the BBB. The authors mention
that this process could be executed via a mechanism similar to
adsorptive transcytosis and uptake by peripheral tissue and be
ACE2-independent. Once the protein enters the brain
parenchyma, it might remain biologically highly active and
toxic, and thus induce detrimental responses in the brain
without the whole virions being involved (92). It should be
added that this research was performed on mouse models and
this mechanism could not be reproduced on a human induced
pluripotent stem cell (iPSC)-based BBB in vitro model.
Nevertheless, this result suggests an interesting avenue that
deserves investigation.
Both inflammation and a potential cytokine storm induce the
loosening of the TJ complex with alterations in the expression of
TJ proteins such as in ZO-1, occludin, claudin-5 and VE-
cadherin (93). Furthermore, cytoskeletal remodeling without a
tight BBB leads to both vascular leakage and coagulation (57).
The viral infection itself and inflammatory molecules bring about
an enhanced permeability of the BBB (91). Through the
compromised BBB, blood monocytes can infiltrate the CNS
and produce a direct infection followed by the rapid activation
of microglia among other glial cells (94). The balance- and type
of cytokines and their cumulative effects at the BBB are complex
and regulated by multiple signaling pathways and cell types.
Next, the whole cascade results in a leaky and impaired BBB.
Perrin and colleagues reported COVID-19 cases in which an
elevated astroglia marker, S100B level was detected as a sign of
increased BBB permeability (95). When an intense systemic
inflammatory response occurs, more virus and peripheral
cytokines such as IL-1b, IL-6, IL-17 and TNF-a, among others,
can enter the brain via the damaged BBB. Hence, exacerbated, or
triggered neuroinflammation by activating microglia, as the key
cellular mediators of this process, may be developed and
intensified by Th17 cells transmigration to the brain
parenchyma and IL-17 upregulation, both caused by the
augmentation of TNF-a (96). Together with the SARS-CoV-2
infection, the cascade promotes a cytokine storm that results in
the increased secretion of pro-inflammatory factors (such as
MIP1-a, IP-10, G-CSF, CRP and ferritin, among others) (97).
Furthermore, the bond between cytokines/chemokines and their
specific receptors on the cerebral microvascular endothelium
provokes in addition to neuroinflammation, BBB breakdown and
encephalitis (97).
Viral Invasion Through the Choroid Plexus
The choroid plexus is a single layer of epithelial cells located in
the brain’s ventricular system, and it produces cerebrospinal
fluid. Neighboring cells of the choroid plexus are interconnected
via TJs and form the BCSFB and contribute to the homeostatic
regulation of the microenvironment in the brain (98). Recently, it
has been found that certain cells of the choroid plexus express the
ACE2 and other SARS-CoV-2 entry factors such as the
TMPRSS2 (99). The same study using iPSC-derived brain
organoids demonstrated that the infection of the choroidFrontiers in Immunology | www.frontiersin.org 8plexus cells by the SARS-CoV-2 causes substantial damage to
the epithelium and a subsequent leakage across this important
barrier. At the same time, the group did not observe infection of
neuronal cells. These results overall suggest that the neurological
symptoms observed in COVID-19 patients might be a secondary
consequence of the infection of supportive CNS cells rather than
the direct infection of neuronal cells (99). This hypothesis has yet
to be confirmed experimentally, although it seems to be in line
with the findings of a post-mortem study of the brains of 43
COVID-19 patients. The authors found no evidence of CNS
damage caused directly by SARS-CoV-2 but found strong
microglia and astrocyte activation and infiltration of cytotoxic
T-lymphocytes (100), which might be a consequence of the
disrupted brain barrier. On the other hand, a new study
revealed the selective susceptibility of dopaminergic cells to
SARS-CoV-2 infection and observed inflammatory and
senescence on the transcriptional level (101), indicating that
this issue among COVID-19 patients might require
special attention.
Olfactory Pathway for Invasion of the CNS
Although the main route for the most viral infections of the lower
airways is considered to be the oral-lung aspiration axis (102,
103), research of the novel coronavirus SARS-CoV-2 suggests
that in this case, the more prevalent entry is via the aspiration of
oropharyngeal mucus originating from the nasal cavity and
containing the viral inoculum, into the deep lung. Evidence
supporting this hypothesis comes from the knowledge that the
nasal lining has a higher concentration of the ACE2 receptor
compared to the lower airways, creating a gradient of high
susceptibility of infection in the nasal cavity to lower parts in
the deep areas of the lung (104). Moreover, the autopsies of
patients who died as a consequence of COVID-19 showed that
the macroscopic appearance of the infected areas of the lungs was
described as “patchy, segmental and peripheral” (104). If the nasal
surface indeed serves as the dominant initial site for SARS-CoV-2
infection, the threat of spreading into the olfactory nerves should
be considered. The olfactory nerve projects from the nasal cavity
directly into the olfactory bulb of the brain, while in the mucosal
part of the nasal cavity, ciliated dendrites of the nerve extend to
the mucus-lined airway space. There they gather odorant
information and transmit it via olfactory sensory neurons’
axons through the cribriform plate directly to the brain (105).
In this way, the olfactory sensory neurons are constantly exposed
to the environment – including the potentially present pathogens
(106); and hence serve as a direct single-cell route for
neuroinvasion. Interestingly, the same study showed that
despite the fact, that viruses can sometimes enter the CNS via
the olfactory nerves and successfully enter the olfactory bulb of
the brain while by-passing the protective barriers, another safety
check is probably in operation in the olfactory bulb. In fact, after
the infection of the olfactory bulb via the olfactory nerve, the
infection was halted before it had the chance to spread to different
CNS areas (106). To achieve such an inhibition of the spread of
viral infection, the immune system needs to be ready to react in a
way that neutralizes the viral particle yet does not damage the
neurons. Such noncytolytic clearance is commonly facilitated byAugust 2021 | Volume 12 | Article 730088
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(CD8+, CD4+ and natural killer cells (NK)) and serve as the
primary protective measure against viruses (107). In the study of
Moseman et al. (106), after the neuroinvasion of the viral particles
to the brain, the first line of defense was represented by microglia,
which shortly after the infection showed evidence of activation.
The activation of cells characterized by the up-regulation of
antigen-presenting molecules MHC I, CD80 and CD86, enabled
microglia to present viral antigens to infiltrating CD8+ T cells.
CD8+ T cells subsequently exert antiviral pressure and stop the
viral spread throughout the CNS. It is interesting that in this
study, microglia were not infected by the virus in question
(vesicular stomatitis virus), yet it was able to present the viral
antigens to T cells. This means that microglia acquired the
antigen from nearby neurons and cross-presented them to the
T cells (106). The scenario of the olfactory nerve infection by
SARS-CoV-2 seems to be plausible as it has been reported that in
many cases, the patients developed progressive ageusia and
anosmia (108). Interestingly, another recent study presented
evidence of the olfactory transmucosal invasion of SARS-CoV-2
infected individuals’ brains. These findings are supported by the
detection of SARS-CoV-2 RNA as well as viral protein in the
brain regions. Moreover, the authors described morphological
changes of the tissue associated with such an infection,
collectively supporting the SARS-CoV-2 neurotropism and the
viral spread along the neuroanatomical structures receiving
projections from the olfactory tract (109).
To determine how exactly the SARS-CoV-2 virus enters the
olfactory nerve and propagates through it into the CNS, the
ACE2 expression levels in the olfactory nerve and the CNS need
to be investigated. Regardless of the manner of entry, once the
virus successfully infects the CNS via the olfactory nerve, further
regions of the brain are involved, such as the piriform and
infralimbic cortices, basal ganglia, and dorsal raphae nuclei,
while other areas such as the thalamus and hypothalamus are
less frequently reported as positive (110). Such a distribution
pattern would suggest a transneuronal spread (111). Despite
these findings, the clear-cut neuro-invasive potential of SARS-
CoV-2 is still yet to be determined, as some research also
indicates that only epithelial (sustentacular) cells of the nasal
mucosa can be infected, not olfactory neurons (112).THE IMPACT OF SARS-CoV-2 ON
MICROGLIA
Gene Expression Modifications via HIF-1a
The family of HIF proteins is transcription regulators that respond
to the prevalent oxygen levels and modify the gene transcription
rates of specific DNA sequences. HIF-1 is a dimer that consists of
HIF-1a and HIF-1b subunits. While HIF-1a is present at very low
levels during normoxia, HIF-1b is continuously transcribed. In
normoxic conditions, HIF-1a is hydroxylated in the presence of
iron, oxygen, and 2-oxoglutarate, then HIF-1a undergoes
ubiquitination and is destroyed (Figure 5) (113). However, in
hypoxemic conditions, the oxygen required for HIF-1a
ubiquitination is lacking. Therefore, HIF-1a does not degrade,Frontiers in Immunology | www.frontiersin.org 9but translocates to the nucleus, where it binds with HIF-1b, then
recruits coactivator proteins at the hypoxia response element.
Numerous target genes that assist in hypoxic adaptation are
upregulated, such as VEGF, which induces angiogenesis, or
erythropoietin, which generates more erythrocytes (114).
However, some genes are downregulated (e.g., PDK1), and this
reduces the oxygen consumption of the mitochondria. The
regulation of genes that boost glucose flux to pyruvate causes a
switch from oxidative to glycolytic cellular metabolism (115).
Furthermore, through endothelial nitric oxide synthase
modulation, HIF-1a can also affect pulmonary circulation (116).
The interaction between HIF-1a and glucose levels is
particularly important, as glycolytic flux is required for SARS-
CoV-2 replication since high glucose levels promote viral
replication and pro-inflammatory cytokine expression (117).
Moreover, ROS are potent inducers of HIF-1a (118). The
mitochondrial ROS (mtROS) production caused by SARS-
CoV-2 stabilizes HIF-1a, which then upregulates IL-1b
expression as well as glycolytic genes. These findings explain
why uncontrolled diabetes can lead to lung dysfunction and a
maladaptive immune response in patients with severe COVID-
19 symptoms. They also suggest that the mtROS/HIF-1a/
glycolysis axis could be a target for treating this disease (117).
Hypoxic State and HIF-1a Expression
Hypoxia plays a central role in endothelial activation and
inflammation, and it creates a positive feedback loop via the
reduction of the expression of the complement regulator CD55
by HIF-1a, IL-2, and TNF-a (119). In hypoxic and inflammatory
microenvironments, HIF-1a is a key driver of myeloid cell
response: (I) It modifies cellular energetics, (II) it upregulates
glycolytic enzymes and glucose transporters to allow ATP
generation under hypoxic conditions, and (III) it prevents the
apoptosis of innate immune cells. In chronic infections, however,
HIF-1a prevented excessive lymphocyte recruitment into lung
interstitium and pathological immune consequences of the host
(120). During the infection of SARS-CoV-2, the infected
monocytes express higher levels of pro-inflammatory cytokines
and multiple forms of IFN, such as IFN-a, b and g (121). The
presence of TNF-a, IL-1b, IL-6, and HIF-1a are associated with
the COVID-19 cytokine storm. Dysregulated blood glucose levels
in diabetic patients are a substantial risk factor for the severity of
the disease. At the same time, elevated glucose levels might
further augment TNF-a, IL-6, and IFN-a/b expression and
initiate a vicious cycle of immune hyperactivity (121).
Hypoxic and Normoxic Conditions
In patients with COVID-19, pneumonia and vascular
permeability are related to the elevated thrombosis (119),
which is stimulated by a hypoxic state in which the
hypercoagulability is increased along with HIF-1a expression
(122). Cells adapt to it by activating HIF-1 and HIF-2, which
promote the expression of a wide array of genes involved in cell
survival and specifically endothelial cell adaptation and energy
metabolism. A transition from HIF-1 to HIF-2 suggests an
adaptation from acute to prolonged hypoxia, although most
genes can be regulated by both (123). HIF-1a has a shortAugust 2021 | Volume 12 | Article 730088
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high turnover, while in hypoxemic conditions, it is conserved
(113). The cytosolic accumulation of succinate also prevents
HIF-1a breakdown (124).
Besides being a coactivator of HIF-1a, pyruvate kinase
isozyme 2 (PKM2) plays a key role in glycolysis and mediates
acute inflammation (125). PKM2 dimers can directly interact
with HIF-1a via nuclear translocation (125, 126). In the nucleus,
HIF-1a regulates the adaptor response to hypoxia (125),
transcribes pro-inflammatory cytokines and glycolytic
machinery (124), especially IL- 1b, a key factor involved in
acute and chronic inflammation and generation of fever
response, and IL-6. This pro-inflammatory shift is
accompanied by the downregulation of anti-inflammatory
cytokines such as IL-10 (126). This condition is distinguished
by excessive neutrophil-predominant inflammation and by
disrupting the alveolar-capillary barrier that causes acute
hypoxemic respiratory failure (127, 128).
The HIF-1 signaling pathway can interact with ErbB, PI3K-
Akt, mTOR pathways and their connected proteins (129). Via a
cascade: PI3K activation phosphorylates Akt, which activates
mTOR. It is followed by the activation of 4E-BP1 and the eIF4
complex by Akt and mTORC1, which causes a translation of
HIF-1a, an effector protein that initiates transcription and
translation of host-specific genes (129, 130). The TNF
signaling pathway is interlinked with HIF-1 signaling; hence, it
can also increase HIF-1a by activating PI3K-Akt, MAPK, and
NF-kB pathways and lead to the overexpression of HIF-1a
mRNA translation and protein synthesis, but not affect its
stability (131).Frontiers in Immunology | www.frontiersin.org 10Microglia in Health and Disease
Microglia are the resident innate immune system cells in the
brain and the first responders to damage of the CNS (132–135).
Besides the maintenance of neuronal homeostasis and
participating in the formation of the BBB (136), microglia
perform critical physiological functions such as synaptic
pruning (137), trophic support of the neurons, the removal of
apoptotic debris (138), and continuous immune surveillance
(139–141). Whenever the brain’s homeostasis is compromised,
microglia can rapidly adapt their phenotype and functions in
response to the signals from their environment, such as cellular
damage or the infiltration of foreign entities (142). Depending on
the nature of the activating signal, microglia change their
phenotype into the phagocytic or cytokine-producing state.
Often, this duality of activation states is referred to as M1
(IFN-g-dependent classical activation; pro-inflammatory
activation) and M2 (IL-4-dependent alternative activation;
repair-inducing/phagocytic) activation states (143), during
which microglia undergo morphological and metabolic
changes in order to efficiently remove the detected threat
(143). Although the long-standing notion of microglial cells
having M1/M2 activation states is widely accepted (144), a
growing body of research indicates that this model might be
oversimplistic considering the complexity of microglial effector
roles in both health and disease (145). However, as the M1/M2
model is in use within the context of microglial responses to the
presence of pathogens, we will adhere to this nomenclature in
the review.
At the time of homeostasis, the quiescent state of microglia is
maintained mainly via the absence of activating factors, and it isFIGURE 5 | Overview of the effects of hypoxia on microglia cells compared to normal oxygen levels. HIF-1a is one of the main components of the response to
hypoxia in myeloid cells. Under normoxic conditions, the oxygen molecules participate in the HIF-1a hydroxylation, ubiquitination and subsequent degradation by the
proteasome complex. In hypoxia, the lack of oxygen molecules prevents ubiquitination and degradation of HIF-1a, which can then translocate to the nucleus and,
together with other co-activating elements, initiate the expression of pro-inflammatory molecules. At the same time, HIF-1a activation might involve crosstalk with
NF-kB, NLRP3 inflammasome, as well as nitric oxide (NO) production along with pro-inflammatory cytokines.August 2021 | Volume 12 | Article 730088
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astroglial cells (e.g. CX3CL1 and CD200) (146). However, in the
presence of an activating signal (e.g. a recognized bacterial or viral
particle), microglia rapidly switch from the homeostatic stage
with ramified morphology to the classically activated (M1) form.
An outcome of an M1 polarizing event is the production of M1-
associated factors such as pro-inflammatory cytokines: TNF-a,
IL-1a, IL-1b, IL-6, IL-12, IL-23; chemokines; REDOX molecules
and other co-stimulatory proteins while phagocytosis is inhibited
during M1 activation (144). However, in the case of detection of
cellular damage, sterile injury or neurodegenerative disease, M2
activation occurs, and the activation pattern includes events that
lead to inflammation resolution through anti-inflammatory
factors (TGF-b, IL-10, IL-13, VEGF, EGF and Arg1) in an
attempt to re-establish homeostasis (147). One of the results of
M2 activation is the transformation of the cells into the amoeboid
type and the activation of phagocytosis, which attempts to remove
cellular debris and recover tissue equilibrium (143).
Inflammation in Viral Infection
As an innate immune response for viral infection in the CNS,
microglial cells transit towards a proinflammatory M1 state and
rapidly proliferate, leading to enhanced phagocytic activity of
microglia (148). During the rapid division of microglial cells, the
so-called Warburg effect occurs, in which the ATP is rapidly
generated by the enhanced glycolytic energy pathway. This
metabolic adaptation is an essential component for the
polarization of microglia besides the increased production of
cytokines such as IL-6 and TNF-a (148). When microglia
polarizing to the M1 state during viral infection, the cells are
likely to be exposed to hypoxic environments, which also
activates HIF-1a expression (148). IFN-a/b genes play a
pivotal role in the potent immune response against viral
infections (149). Due to the interaction between the INF-a/b
signaling and the IFN-g pathway, microglia may become more
responsive to the virus by its INF-g antiviral program (150).
Furthermore, the results of Zhou et al. clearly show that IFN
priming prior to tissue cell infection with SARS-CoV results in
the augmented expression of several molecules involved in the
induction and upregulation of signaling pathways of IFN-b,
among other factors (151).
Although astrocytes are the main source of IFN-a/b in mice
(152), in the case of direct viral encephalitis, infected microglia
also contribute to IFN-I production, which is dependent on
signaling via the IFN-a/b receptor in an MDA-5 dependent
pathway (153). Besides the IFN family, the critical role of IL-10
was found during an emerging inflammation caused by a viral
infection. CD4+ cells are the pivotal source of IL-10, which
cytokine blocks the production of IFN-g of CD4+ lymphocytes.
In the absence of IL-10, higher levels of INF-g mRNA and
protein were produced by CD4+ cells without alterations in the
functions of CD8+ lymphocytes. In coronavirus infections, not
only high numbers of microglia expressed iNOS and MHC-II,
but the viral clearance was also more rapid in lesions of IL-10
deficient mice (154). Overall, in viral infections, the absence of
IL-10 results in demyelination and cell death, while the presence
of IL-10 protects against tissue damage.Frontiers in Immunology | www.frontiersin.org 11Along with the above-mentioned processes, the inflammatory
stimulus in COVID-19 can also be initiated by the cascade of a
viral infection that can, in turn, activate the lung macrophages
and affect the neutrophil influx; and this indirectly leads to
NLRP3 inflammasome activation (155). NLRP3 inflammasome
is crucial for the induction of acute lung injury when IL-1b
signaling is induced by hypoxia. Similar to hypoxic alveolar
macrophages in the lungs, microglia in the brain are the primary
source of IL-1b (152). A higher level of another cytokine, IL-6,
was observed in parallel with the downregulation of microglial
functions in the case of hypoxia. Here, the pathological driver is
the existent IL-6-mediated cytokine storm, which appears within
two days, leading to neurotoxicity in less than a week (156).
While astrocytes are the source of IL-6, an increased
hypothalamic IL-6 level was observed along with microglia
activation caused by lung infection (157). In contrast, a
blockade of microglia in a hypoxic state led to induced
astrocytic IL-6 production. A specific therapeutic blockade of
circulating IL-6 can be achieved using tocilizumab or siltuximab,
but the efficiency of such treatment is relatively low (158).The Role of Self Molecules in
Microglia Activation
In general, when cells are injured, the normally intracellular
molecules, such as ATP, appear in the extracellular space and
serve as a danger-associated molecule pattern (DAMP), which is
recognized by the PRRs of the macrophages (157). Therefore,
this inflammatory cascade can be initiated by the activation of
macrophages by upregulated cytosolic PRR signaling pathways
in response to the tissue damage caused by SARS-CoV-2.
Through the blood circulation, having released into the brain
parenchyma, DAMPs and SARS-CoV-2-derived PAMPs can
reactivate microglia. The activation of PRRs on microglia
initiates the antiviral cascade via e.g.: the NF-kB (158). The
production of IFN-I and -III promotes intracellular antiviral
defense and the production and release of microglia and
macrophage-dependent IL-1b and IL-6, are the primary
response to viral infection (157). However, like M protein or N
protein in the SARS-CoV, in SARS-CoV-2 these viral proteins
can block the formation of the TRAF3, TANK and TBK1/IKK
complex (159); and thereby inhibit the production of IFN-I,
which happens in the case of dendritic cells (160). Additionally,
elevated levels of IL-12, p40, TNF-a, IL-15, IL-6, and IL-1b, on
both mRNA and protein levels, were observed in a neuron
culture infected by a murine neurotrophic b Coronavirus then
both in non-neurotrophic virus, MHV-2 infected cells and in the
uninfected control cultures (161). Overall, microglia may
contribute to viral control and nervous tissue damage in
response to SARS-CoV-2 CNS infection (158, 159, 162); and
thereby inhibit the production of IFN-I, which happens in the
case of dendritic cells (160). Additionally, elevated levels of IL-12,
p40, TNF-a, IL-15, IL-6, and IL-1b, on both mRNA and protein
levels, were observed in a neuron culture infected by a murine
neurotrophic b Coronavirus then both in non-neurotrophic
virus, MHV-2 infected cells and in the uninfected control
cultures (161). Supporting the idea, the quantities of cytokinesAugust 2021 | Volume 12 | Article 730088
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levels are high in the absence of microglia (153).CONCLUSION
In this review, we have systematically described and analyzed the
existing information on possible connections between infection-
induced pulmonary events and neurological symptoms. Our
analyses might encourage researchers to find early biomarkers
and targeted therapeutic approaches to inhibit and/or block the
development of neurologic symptoms.
The reported neurological problems in COVID-19 patients
might come from the overstimulation of the immune system,
and it is presumed that there is a strong involvement of microglia
and possibly astroglia in response to peripheral inflammation
rather than direct viral infection of the CNS (163). The described
events could lead to an interplay between the lung and the brain
in the case of SARS-CoV-2 infection, which is based on the fact
that the hypoxia and systemic oxidative stress couple the
disrupted respiratory epithelium to brain damage. It is known
that during COVID-19 infection, there is an increased
production of cytokines and chemokines in the periphery,
especially in the lung macrophages and in bronchial epithelial
cells. When hypoxia occurs owing to difficulties in breathing, a
significant amount of proinflammatory factors is released due to
the activation of HIF-1a. Certainly, in cases of prolonged and
substantial elevation of cytokines in the blood, these can cross the
BBB and activate microglia. Similarly, in the case of hypoxia, the
lack of oxygen is inevitably sensed by the brain microglia, and
this leads to its activation. In a healthy brain, this kind of
activation might induce neuroinflammation and potentially
lead to neuropsychiatric or neurodegenerative disorders. More
severe effects of hypoxia are expected in those patients with pre-
existing neurodegenerative diseases, including those which are
pre-symptomatic and thus have not yet been diagnosed. In a
relevant scenario for Alzheimer’s disease, it has been shown that
hypoxia is a major risk factor. Specifically, HIF-1a upregulation
in hippocampal microglia leads to reduced Ab elimination by
microglia and hence to increased Ab-associated neuropathology
(164). Knowing that both hypoxia and increased levels of
systemic cytokine levels are very likely to cause some degree of
damage to the brain, this possibility should not be overlooked
and need to be investigated in the future.
Although the predominant clinical symptoms of COVID-19 are
pulmonary issues with respiratory manifestations, neurological
symptoms are increasingly noted. The loss of smell and taste was
reported among the first non-respiratory symptoms, and many
people reported otolaryngologic symptoms, headaches, fatigue, and
a state called “brain fog” – a condition where patients had trouble
thinking clearly (165). All these symptoms suggest possible effects
of SARS-CoV-2 on the CNS. Several research groups examined the
potential of viral particles of SARS-CoV-2 to invade the CNS tissue,
and also the presence of the virus was confirmed in cerebrospinal
fluid taken from an encephalitis patient by next-generation
sequencing (24) as well as the presence of CSF-specific antiFrontiers in Immunology | www.frontiersin.org 12−SARS−CoV−2 antibodies (67). Furthermore, recently in human
3D organoids, it was shown that SARS-CoV-2 is indeed able to
infect and kill neurons (166). A preprint publication by Chen et al.
(101), claims that human pluripotent stem cell-derived midbrain
dopamine neurons are selectively permissive to SARS-CoV-2
infection, with potential long-term implications for the risk of
developing Parkinson’s disease-related symptoms. Nevertheless,
despite finding further proofs of SARS-CoV-2 protein expression
in the brains of the deceased COVID-19 patients, so far, it was not
successfully proven that the presence of the virus is directly
associated with the neuropathological changes (100). It is
important to mention that the study of Song et al. (67) show
evidence of the existence of antineuronal autoantibodies that were
detectable specifically in COVID-19 patients, while the exact
pathogenic relevance of these is yet to be discovered. In the
meantime, these autoantibodies could be considered as one of
the possible indirect source/contributors to COVID−19 related
neuropathology. Presence of such autoantibodies is quite similar to
prothrombotic autoantibodies causing occlusion of blood vessels
identified recently in Covid-19 patients (75). Moreover, the same
study hypothesizes about the similarities between severe COVID
−19 phenotypes and those present in patients with lupus and
antiphospholipid syndrome, both of which are typical for the
presence of anti-phospholipid autoantibodies, and in extremely
severe cases, can cause multiple organ failure (75). Additionally, a
growing number of case reports describing a connection between
SARS−CoV−2 and the Guillain-Barré syndrome (GBS) has
emerged recently (167–171). GBS is a state of acute limb
paralysis caused typically by an antecedent infectious disease
(often a gastrointestinal or respiratory infection) or other
immune stimulation that induces an aberrant autoimmune
response that targets peripheral nerves and leads to weakness
and loss of sensation (172, 173). The reported cases of COVID
−19-associated GBS highlight the similarities with cytomegalovirus,
Zika virus, and HIV-associated GBS, and thus also suggest a
neuroinvasive potential of SARS−CoV−2 (170). At the same
time, these findings further underline the importance of immune
modulation and autoimmune processes in SARS−CoV−2 infected
patients. Therefore, it is very likely that together with other
pathological events occurring during COVID−19 illness,
detrimental autoimmune effects could contribute to the overall
disease progress.
A small Swedish clinical trial demonstrated that CSF of
COVID-19 patients with neurological symptoms showed an
elevated neurofilament light chain protein (NfL) level that
resembles axon injury. Furthermore, the elevated NfL level in the
CSF correlated with the seriousness of the neurological symptoms
(Glasgow Coma Scale) and was higher in patients between serious
and critical disease as compared with mild and moderate disease
(174). Based on this, wider clinical trials are much needed to find
reliable biomarkers for CNS injury to support the early
rehabilitation of COVID-19 patients and to avoid the
development of long-COVID. It is currently too early to tell
what exactly the long-term effects of COVID-19 on patients’
mental health will be. With so many infected people worldwide,
the overall number of patients with neurological complicationsAugust 2021 | Volume 12 | Article 730088
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costs (175). Moreover, even though the proportion of acute
infections with neurological symptoms remains relatively small,
neurological complications can lead to lifelong problems.
Furthermore, in the cases of patients from the intensive care
unit, it had been pointed out that several cases of brain injury
could have escaped the attention due to patients being in a state of
induced coma, and specific neurological examinations such as
imaging were often undertaken only in those people that were
slow to wake (83). At the same time, it should be kept in mind that
many cases of COVID-related chronic neurological symptoms
might not have been reported yet. Considering the global
healthcare crisis caused by prioritizing COVID-19 patients with
acute and life-threatening conditions, perhaps only after this crisis
other COVID-related chronic complications will emerge.
Therefore, it is of major importance to provide follow-up studies
to determine the long-term neurological effects of this disease.
Additionally, it has been observed that the course and the
pathological consequences of COVID−19 might differ from
patient to patient, future studies on the pathobiological
mechanisms and contributing factors will be essential. For
example, it would be important to describe the associated risk
factors (including those of genetic origin), that can possibly
contribute to the different disease outcomes in individual
patients. Next, identification of biomarkers that help distinguish
between direct viral infection of the brain and immune
overactivation would be essential for the selection of proper
treatment. Altogether, such knowledge would provide leverage in
early recognition and short and long-term management of the
disease and perhaps open new opportunities for personalized
medicine based on the individual background and risk factors of
each patient.Frontiers in Immunology | www.frontiersin.org 13AUTHOR CONTRIBUTIONS
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ACE2 Angiotensin-converting enzyme 2
ADAM17 A Disintegrin And Metalloprotease 17
Ang II Angiotensin II
Arg1 Arginase 1
BBB Blood-brain barrier
BCSFB Blood-cerebrospinal fluid barrier
BMVEC Brain microvascular endothelial cells
BRB Blood-retina barrier
CCL2/3 C–C motif chemokine ligand 2/3
CD Cluster of differentiation
CD4+/CD8+ Cluster of differentiation 4/8
CNS Central nervous system
COVID-19 Coronavirus disease 2019
CRP C-reactive protein
CSF Cerebrospinal fluid
CSF1R Colony stimulating factor 1 receptor
CX3CL1 Chemokine (C-X3-C motif) ligand 1
CXCL10 Chemokine (C-X-C motif) ligand 10
DAMP Damage-associated molecular pattern
DNA Deoxyribonucleic acid
EGF Epidermal growth factor
ErbB Epidermal growth factor receptor family
GBS Guillain-Barré syndrome
GCSF Granulocyte colony-stimulating factor
HCoV Human coronavirus
HIF-1a Hypoxia-inducible factor 1-alpha




iNOS Inducible nitric oxide synthase
IP-10 Interferon gamma-induced protein 10
iPSC Induced pluripotent stem cell
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M protein Myeloma protein
MAPK Mitogen-activated protein kinase
MAVS Mitochondrial antiviral signaling
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MHV Mouse hepatitis virus
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mTOR Mechanistic target of rapamycin
mtROS Mitochondrial reactive oxygen species
N protein Nucleocapsid protein
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NF-kB Nuclear factor-kappa B
NK cells Natural killer cells
NLRP3 NLR family pyrin domain containing 3
ORFs Open reading frames
p40 P40 Protein
PAMP Pathogen-associated molecular pattern
PDK1 Phosphoinositide-dependent kinase-1
PI3K-Akt Phosphoinositide 3-kinase - Protein kinase B
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PRR Pattern recognition receptor
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ROS Reactive oxygen species
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S100B S100 calcium-binding protein B
SARS-CoV-1/-2 Severe acute respiratory syndrome coronavirus 1/2
STAT Signal transducer and activator of transcription protein
TANK TRAF family member-associated NF-kappa-B activator
TBK1/IKK TANK-binding kinase 1
TGF-b Transforming growth factor beta
TLR-3/TLR-7 Toll-like receptor 3/7
TMPRSS2 Transmembrane protease, serine 2
TNF-a Tumor necrosis factor
TRAF3/6 Tumor necrosis factor receptor-associated factor 3/6
VEGF Vascular endothelial growth factor
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